Abstract
Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
Keywords: Acetylcholine, acetylcholinesterase inhibitors, Alzheimer disease, cholinergic pathways, MCI, mild cognitive impairment, RBD, REM behavior disorder, REM, rivastigmine (RVT), sleep.
Current Alzheimer Research
Title:Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Volume: 11 Issue: 3
Author(s): Valerio Brunetti, Anna Losurdo, Elisa Testani, Leonardo Lapenta, Paolo Mariotti, Camillo Marra, Paolo Maria Rossini and Giacomo Della Marca
Affiliation:
Keywords: Acetylcholine, acetylcholinesterase inhibitors, Alzheimer disease, cholinergic pathways, MCI, mild cognitive impairment, RBD, REM behavior disorder, REM, rivastigmine (RVT), sleep.
Abstract: Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
Export Options
About this article
Cite this article as:
Brunetti Valerio, Losurdo Anna, Testani Elisa, Lapenta Leonardo, Mariotti Paolo, Marra Camillo, Rossini Maria Paolo and Marca Della Giacomo, Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment, Current Alzheimer Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567205011666140302195648
DOI https://dx.doi.org/10.2174/1567205011666140302195648 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Treatment of Inflammatory and Paraproteinemic Neuropathies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Current Molecular Medicine Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science Gymnema sylvestre R. Br., an Indian Medicinal Herb: Traditional Uses, Chemical Composition, and Biological Activity
Current Pharmaceutical Biotechnology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ivabradine: A Current Overview
Current Clinical Pharmacology Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents Editorial (Hot Topic: Recent Advances in Neonatal Pharmacology)
Current Drug Metabolism